Phyo Than Htoo (Phyo T Htoo)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Ankylosing Spondylitis

Cardiovascular Disease

Top Venues

Annals of internal medicine

American journal of epidemiology

This page only lists publications with an associated author ORCID identifier.

Publications

Phyo Than Htoo, Jessie K Edwards, Mugdha Gokhale, Virginia Pate, John B Buse, Michele Jonsson-Funk, Til Stürmer
A Systematic Approach to Evaluating Instrumental Variable Assumptions: Applied Example of Glucose-lowering Medications and Risk for Hospitalized Heart Failure in Older Adults. American journal of epidemiology (2024)
Phyo Than Htoo, Mehdi NajafZadeh, Helen Tesfaye, Sebastian Schneeweiss, Deborah J Wexler, Robert J Glynn, Niklas Schmedt, Anouk Déruaz-Luyet, Lisette Koeneman, Julie M Paik, Elisabetta Patorno
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes. Diabetes care (2024)
Phyo Than Htoo, Helen Tesfaye, Sebastian G Schneeweiss, Deborah J Wexler, Brendan M Everett, Robert J Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M Paik, Elisabetta Patorno
Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia (2024)
Phyo Than Htoo, Helen Tesfaye, Sebastian G Schneeweiss, Deborah J Wexler, Brendan M Everett, Robert J Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M Paik, Elisabetta Patorno
Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia 67 (7) (2024)
Phyo Than Htoo, Robert J Glynn, Shirley V Wang, Julie M Paik, Sebastian G Schneeweiss, Alexander Muir Walker, Elisabetta Patorno
Stratified analysis in comparative effectiveness studies that emulate randomized trials. Pharmacoepidemiology and drug safety (2023)
Phyo Than Htoo, Julie M Paik, Ethan M Alt, Dae Hyun Kim, Deborah J Wexler, Seoyoung C Kim, Elisabetta Patorno
Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk. The journals of gerontology. Series A, Biological sciences and medical sciences (2023)
Elisabetta Patorno, Phyo Than Htoo, Brendan M Everett, Seoyoung C Kim
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of internal medicine 175 (1) (2022)
Elisabetta Patorno, Phyo Than Htoo, Robert J Glynn, Sebastian G Schneeweiss, Deborah J Wexler, Ajinkya Pawar, Lily G Bessette, Kristyn Chin, Brendan M Everett, Seoyoung C Kim
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of internal medicine 175 (1) (2022)
Phyo Than Htoo, John B Buse, Matthew A Cavender, Tiansheng Wang, Virginia Pate, Jessie K Edwards, Til Stürmer
Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. Journal of the American Heart Association 11 (4) (2022)
Elisabetta Patorno, Phyo Than Htoo, Robert J Glynn, Sebastian G Schneeweiss, Deborah J Wexler, Ajinkya Pawar, Lily G Bessette, Kristyn Chin, Brendan M Everett, Seoyoung C Kim
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of internal medicine 174 (11) (2021)